Dose-Dependent INhibitory Effect of RosuVastatin In Japanese PatienTs with Acute Myocardial InfarcTION on Serum Concentration of Matrix Metalloproteinases

INTERVENTION: Rosuvastatin 10mg/day (n=60) (Starting dose: 5mg/day) Rosuvastatin 2.5mg/day (n=60) CONDITION: Hypercholesterolemic patients with AMI PRIMARY OUTCOME: The percent change of MMPs at 24 weeks after administration SECONDARY OUTCOME: 1. The change and the changes rate in LDL‐C, HDL‐C, TG, LDL‐C/HDL‐C ratio at 1day, 4weeks, and 24 weeks after administration.; 2. The change and the changes rate of inflammatory markers and cardiac markers at 1day, 4weeks, and 24 weeks after administration. ; 3. The change and the changes rate of inflammatory markers in the aortic root and the coronary sinus at 24 weeks after administration.; 4. The change of the plaque volume and stabilization at 24 weeks after administration.; 5. Correlation between the lipid parameters, inflammatory markers, and other parameters.; 6. Achievement rates of lipid parameters according to guidelines.; 7. Incidence of cerebro‐cardiovascular events.; 8. Incidence and types of adverse events. INCLUSION CRITERIA: Patients meeting the following inclusion criteria will be included in the study: 1) Successful PCI for AMI 2) Hypercholesterolmia (LDL‐C > 100mg/dL) 3) Giving voluntary written consent to participate in the study 4) 20 years old or older